BioTech

Roche Announces Positive CHMP Recommendation For Susvimo

July 24, 2026 — 06:37 am EDT

Written by RTTNews.com for RTTNews

(RTTNews) - Roche (RO.SW, ROG.SW) announced that the European Medicines Agency's Committee for Medicinal Products for Human Use has recommended the approval of Susvimo 100 mg/mL for the treatment of neovascular age-related macular degeneration. A final decision is expected from the European Commission in the near future.

Levi Garraway, Roche's Chief Medical Officer and Head of Global Product Development, said: "By requiring only two refills per year, Contivue with Susvimo offers a continuous drug delivery approach intended to reduce the frequency of clinic visits, with data from clinical trials supporting maintenance of vision up to seven years."

Roche shares are trading on the SIX Swiss Exchange at 350.80 Swiss francs, up 0.37%.

For More Such Health News, visit rttnews.com.

RTTNews
Founded in the late 1990s by Andrew Mariathasan in New York, with the goal of covering Wall Street for a new generation of investors, RTTNews has expanded steadily over the years to become a trusted provider of content for a wide array of subjects across several platforms. RTT's Financial Newswire is relied upon by some of the world's largest financial institutions, including banks, brokerages, trading platforms and financial exchanges.
More articles by this source

Tags

BioTech
Stocks Mentioned

Latest Articles
Data is currently not available